InvestorsHub Logo
Followers 22
Posts 1379
Boards Moderated 0
Alias Born 03/31/2017

Re: farrell90 post# 211400

Thursday, 01/04/2018 6:12:38 AM

Thursday, January 04, 2018 6:12:38 AM

Post# of 403568
farrell90,

Awsome summary and reminder.

Thank you!

Go Leo & IPIX!

IPIX will be pounding the FDA's door for Break Through Designation.

Brilacidin for Oral Mucositis touches all the bases laid out by the FDA for Break Through Designation:
-Effective treatment is not currently available
-Two solid FDA phase studies for Brilicidin completed
-Great safety profile
-Easy dosage and application as an oral rise

Plus it will be used as a preventative treatment

The real reason Brilacidin will be approved is because Oral Mucosiditis is a miserable, painful, debilitating problem which complicates all aspects of care for cancer patients without any current effective treatment... until now.

OM complicates cancer treatment. Many patients have their treatment delayed or suspended.

OM interupts their nutrition at a time when good nutrition is imperative for their survival. It can even result in the need for Gastric feeding tube placement.

OM is psychologically devastating to cancer patients and can lead to patients deciding to stop all treatment..

An effective treatment for Oral Mucositis has to be a key goal for cancer care.

The FDA is very aware of its importance and the lack of current effective treatments.

Good luck, Farrell

updated from my earlier post 206478:

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IPIX News